— Know what they know.
Not Investment Advice

VNDA NASDAQ

Vanda Pharmaceuticals Inc.
1W: -3.7% 1M: -22.0% 3M: -23.6% YTD: -52.2% 1Y: -28.2% 3Y: -8.6% 5Y: -78.2%
$3.99
+0.05 (+1.27%)
After Hours: $3.92 (-0.07, -1.75%)
Weekly Expected Move ±5.0%
$4 $4 $4 $4 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 31 · $238.2M mcap · 57M float · 1.65% daily turnover · Short 58% of daily vol
Credit Risk of going bust: higher than 65% of companies Debt: 8.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 99%), Vanda Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $22.8M against a stock market value of $238.2M.
Distance to default 3.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $11.4M (short-term plus half of long-term), stock volatility 78.5%; Altman Z'' -4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$216M
Revenue
+6.0% YoY
$-275M
Net Income
-310.6% YoY
$-193M
Free Cash Flow
-193.5% YoY
93.0%
Gross Margin
-126.3%
Op. Margin
-123.7%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-77.8%
ROA-53.0%
ROIC-201.0%

Valuation

P/E-0.9
P/B1.1
EV/EBITDA-1.3

Leverage

Debt/Equity0.10
Current Ratio1.61
Interest Cov.0.0x

Quality Scores

Piotroski F3/9
Altman Z-1.22
Beneish M-3.36

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms